157 related articles for article (PubMed ID: 24103580)
1. Novel 6β-acylaminomorphinans with analgesic activity.
Váradi A; Hosztafi S; Le Rouzic V; Tóth G; Urai Á; Noszál B; Pasternak GW; Grinnell SG; Majumdar S
Eur J Med Chem; 2013 Nov; 69():786-9. PubMed ID: 24103580
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, and biological evaluation of 6alpha- and 6beta-N-heterocyclic substituted naltrexamine derivatives as mu opioid receptor selective antagonists.
Li G; Aschenbach LC; Chen J; Cassidy MP; Stevens DL; Gabra BH; Selley DE; Dewey WL; Westkaemper RB; Zhang Y
J Med Chem; 2009 Mar; 52(5):1416-27. PubMed ID: 19199782
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, and biological evaluation of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4'-pyridyl)carboxamido]morphinan derivatives as peripheral selective μ opioid receptor Agents.
Yuan Y; Elbegdorj O; Chen J; Akubathini SK; Zhang F; Stevens DL; Beletskaya IO; Scoggins KL; Zhang Z; Gerk PM; Selley DE; Akbarali HI; Dewey WL; Zhang Y
J Med Chem; 2012 Nov; 55(22):10118-29. PubMed ID: 23116124
[TBL] [Abstract][Full Text] [Related]
4. Exploring pharmacological activities and signaling of morphinans substituted in position 6 as potent agonists interacting with the μ opioid receptor.
Ben Haddou T; Malfacini D; Calo G; Aceto MD; Harris LS; Traynor JR; Coop A; Schmidhammer H; Spetea M
Mol Pain; 2014 Jul; 10():48. PubMed ID: 25059282
[TBL] [Abstract][Full Text] [Related]
5. Effect of a 6-cyano substituent in 14-oxygenated N-methylmorphinans on opioid receptor binding and antinociceptive potency.
Spetea M; Greiner E; Aceto MD; Harris LS; Coop A; Schmidhammer H
J Med Chem; 2005 Jul; 48(15):5052-5. PubMed ID: 16033285
[TBL] [Abstract][Full Text] [Related]
6. Discovery of Peripheral κ-Opioid Receptor Agonists as Novel Analgesics.
Suzuki S; Sugawara Y; Inada H; Tsuji R; Inoue A; Tanimura R; Shimozono R; Konno M; Ohyama T; Higashi E; Sakai C; Kawai K
Chem Pharm Bull (Tokyo); 2017; 65(11):1085-1088. PubMed ID: 29093296
[TBL] [Abstract][Full Text] [Related]
7. Drug design and synthesis of epsilon opioid receptor agonist: 17-(cyclopropylmethyl)-4,5alpha-epoxy-3,6beta-dihydroxy-6,14-endoethenomorphinan-7alpha-(N-methyl-N-phenethyl)carboxamide (TAN-821) inducing antinociception mediated by putative epsilon opioid receptor.
Fujii H; Narita M; Mizoguchi H; Murachi M; Tanaka T; Kawai K; Tseng LF; Nagase H
Bioorg Med Chem; 2004 Aug; 12(15):4133-45. PubMed ID: 15246090
[TBL] [Abstract][Full Text] [Related]
8. Identification of opioid ligands possessing mixed micro agonist/delta antagonist activity among pyridomorphinans derived from naloxone, oxymorphone, and hydromorphone [correction of hydropmorphone].
Ananthan S; Khare NK; Saini SK; Seitz LE; Bartlett JL; Davis P; Dersch CM; Porreca F; Rothman RB; Bilsky EJ
J Med Chem; 2004 Mar; 47(6):1400-12. PubMed ID: 14998329
[TBL] [Abstract][Full Text] [Related]
9. Morphinan derivatives with an oxabicyclo[3.2.1]octane structure as dual agonists toward δ and κ opioid receptors.
Uenohara Y; Tsumura S; Hirayama S; Higashi E; Watanabe Y; Gouda H; Nagase H; Fujii H
Bioorg Med Chem; 2022 Jan; 53():116552. PubMed ID: 34894610
[TBL] [Abstract][Full Text] [Related]
10. Synthesis, opioid receptor binding, and biological activities of naltrexone-derived pyrido- and pyrimidomorphinans.
Ananthan S; Kezar HS; Carter RL; Saini SK; Rice KC; Wells JL; Davis P; Xu H; Dersch CM; Bilsky EJ; Porreca F; Rothman RB
J Med Chem; 1999 Sep; 42(18):3527-38. PubMed ID: 10479286
[TBL] [Abstract][Full Text] [Related]
11. Synthesis of 6,14-epoxymorphinan derivatives and their pharmacologies.
Nemoto T; Yamamoto N; Watanabe A; Fujii H; Hasebe K; Nakajima M; Mochizuki H; Nagase H
Bioorg Med Chem; 2011 Feb; 19(3):1205-21. PubMed ID: 21256034
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and pharmacological activities of 6-glycine substituted 14-phenylpropoxymorphinans, a novel class of opioids with high opioid receptor affinities and antinociceptive potencies.
Spetea M; Windisch P; Guo Y; Bileviciute-Ljungar I; Schütz J; Asim MF; Berzetei-Gurske IP; Riba P; Kiraly K; Fürst S; Al-Khrasani M; Schmidhammer H
J Med Chem; 2011 Feb; 54(4):980-8. PubMed ID: 21235243
[TBL] [Abstract][Full Text] [Related]
13. Synthesis of quinolinomorphinan derivatives as highly selective δ opioid receptor ligands.
Ida Y; Matsubara A; Nemoto T; Saito M; Hirayama S; Fujii H; Nagase H
Bioorg Med Chem; 2012 Oct; 20(19):5810-31. PubMed ID: 22967810
[TBL] [Abstract][Full Text] [Related]
14. Morphine can produce analgesia via spinal kappa opioid receptors in the absence of mu opioid receptors.
Yamada H; Shimoyama N; Sora I; Uhl GR; Fukuda Y; Moriya H; Shimoyama M
Brain Res; 2006 Apr; 1083(1):61-9. PubMed ID: 16530171
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and opioid receptor binding affinities of 2-substituted and 3-aminomorphinans: ligands for mu, kappa, and delta opioid receptors.
Decker M; Si YG; Knapp BI; Bidlack JM; Neumeyer JL
J Med Chem; 2010 Jan; 53(1):402-18. PubMed ID: 19928862
[TBL] [Abstract][Full Text] [Related]
16. Synthesis, opioid receptor binding, and bioassay of naltrindole analogues substituted in the indolic benzene moiety.
Ananthan S; Johnson CA; Carter RL; Clayton SD; Rice KC; Xu H; Davis P; Porreca F; Rothman RB
J Med Chem; 1998 Jul; 41(15):2872-81. PubMed ID: 9667975
[TBL] [Abstract][Full Text] [Related]
17. Novel ligands for the opioid receptors: synthesis and structure-activity relationships among 5'-aryl and 5'-heteroaryl 17-cyclopropylmethyl-4,5 alpha-epoxypyrido[2',3':6,7]morphinans.
Ananthan S; Khare NK; Saini SK; Davis P; Dersch CM; Porreca F; Rothman RB
Bioorg Med Chem; 2003 Sep; 11(18):4143-54. PubMed ID: 12927876
[TBL] [Abstract][Full Text] [Related]
18. Design and synthesis of novel bivalent ligands (MOR and DOR) by conjugation of enkephalin analogues with 4-anilidopiperidine derivatives.
Deekonda S; Wugalter L; Rankin D; Largent-Milnes TM; Davis P; Wang Y; Bassirirad NM; Lai J; Kulkarni V; Vanderah TW; Porreca F; Hruby VJ
Bioorg Med Chem Lett; 2015 Oct; 25(20):4683-8. PubMed ID: 26323872
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological characterization of ATPM [(-)-3-aminothiazolo[5,4-b]-N-cyclopropylmethylmorphinan hydrochloride], a novel mixed kappa-agonist and mu-agonist/-antagonist that attenuates morphine antinociceptive tolerance and heroin self-administration behavior.
Wang YJ; Tao YM; Li FY; Wang YH; Xu XJ; Chen J; Cao YL; Chi ZQ; Neumeyer JL; Zhang A; Liu JG
J Pharmacol Exp Ther; 2009 Apr; 329(1):306-13. PubMed ID: 19136637
[TBL] [Abstract][Full Text] [Related]
20. 14-Alkoxy- and 14-acyloxypyridomorphinans: μ agonist/δ antagonist opioid analgesics with diminished tolerance and dependence side effects.
Ananthan S; Saini SK; Dersch CM; Xu H; McGlinchey N; Giuvelis D; Bilsky EJ; Rothman RB
J Med Chem; 2012 Oct; 55(19):8350-63. PubMed ID: 23016952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
